Biopharma PEG Scientific Inc news

Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. The assigned DMF number is 041864.

This significant achievement underscores Biopharma PEG's robust research and developme

Biopharma PEG, a leading manufacturer of high-quality polyethylene glycol (PEG) derivatives, today announced that its mPEG-pAld (20K) product has successfully achieved DMF (Drug Master File) registration with the U.S. Food and Drug Administration (FDA) under DMF number 040600.

“We are thrilled to receive FDA DMF registration for our mPEG-pAld (20K) product,” said Sonia Lee, Marketing Director at Biopharma PEG. “This achievement demonstrates our commitment to providing

Watertown, MA — November 25, 2024—In the spirit of Thanksgiving, Biopharma PEG Scientific Inc. would like to express its sincere gratitude to our esteemed customers and partners for their trust and support. It is a privilege to collaborate with you, and we look forward to further strengthening our partnership in the future.

As a gesture of our appreciation, we are pleased to announce a 30% discount on a selection of our monodispersed PEGs for a limited time. This special offer is va

Watertown, MA — October 24, 2024 — Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.

PEGylation provides numerous advantages

Biopharma PEG, a key provider of premium polyethylene glycol (PEG) derivatives, is thrilled to announce a substantial expansion of its large-scale Good Manufacturing Practice (GMP) production capabilities. This strategic move is aimed at addressing the rising global demand for Lipid Nanoparticles (LNPs), which are vital for nucleic acid drug delivery, especially in mRNA-based therapies and vaccines.

Lipid Nanoparticles have become a groundbreaking delivery mechanism within the biopharm